Distribution of chromogranin B-like immunoreactivity in the human hippocampus and its changes in Alzheimer’s disease

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Acta Neuropathologica

• Publication date

  2000-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/s004010000239PMID 10963369
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nucleotide sequence and cellular distribution of rat chromogranin B (secretogranin I) mRNA in the neuroendocrine system

  2008cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  2002cited by this paper
• PE-11, a peptide derived from chromogranin B, in the human brain.

  1999cited by this paper
• Neuropeptide abnormalities in patients with early Alzheimer disease.

  1999cited by this paper
• Neurochemical Dissection of Synaptic Pathology in Alzheimer's Disease

  1998cited by this paper
• Synaptic loss reflected by secretoneurin‐like immunoreactivity in the human hippocampus in Alzheimer's disease

  1998cited by this paper
• The Disulfide-bonded Loop of Chromogranins, Which Is Essential for Sorting to Secretory Granules, Mediates Homodimerization*

  1998cited by this paper
• Abeta associated neuropil changes: correlation with neuronal loss and dementia.

  1998cited by this paper
• Synaptic density in the inner molecular layer of the hippocampal dentate gyrus in Alzheimer disease.

  1998cited by this paper
• New neuropathological criteria for Alzheimer disease.

  1998cited by this paper
• Neuropathology of Alzheimer's disease: a critical update.

  1998cited by this paper
• Corticotropin‐Releasing Factor (CRF), CRF‐Binding Protein (CRF‐BP), and CRF/CRF‐BP Complex in Alzheimer's Disease and Control Postmortem Human Brain

  1997cited by this paper
• Neuropathological staging of Alzheimer-related lesions: the challenge of establishing relations to age.

  1997influential reference
• Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease.

  1997cited by this paper
• Differential vasopressin and oxytocin innervation of the human parabrachial nucleus: no changes in Alzheimer's disease.

  1996cited by this paper
• Rat Brain: Distribution of Immunoreactivity of PE‐11, a Peptide Derived from Chromogranin B

  1996influential reference
• Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex.

  1996cited by this paper
• Entorhinal cortex modules of the human brain

  1996cited by this paper
• Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease.

  1995cited by this paper
• Correlations of synaptic and pathological markers with cognition of the elderly.

  1995cited by this paper
• Reduction of the disulfide bond of chromogranin B (secretogranin I) in the trans‐Golgi network causes its missorting to the constitutive secretory pathways.

  1993cited by this paper
• Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles.

  1992cited by this paper
• Sites of synthesis of chromogranins A and B in the human brain.

  1992cited by this paper
• The granin (chromogranin/secretogranin) family.

  1991cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease.

  1991cited by this paper
• The distribution of chromogranin A—like immunoreactivity in the human hippocampus coincides with the pattern of resistance to epilepsy‐induced neuronal damage

  1990cited by this paper
• Neuropeptides and Alzheimer's Disease

  1990cited by this paper
• The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease

  1988cited by this paper
• Chromogranin B (secretogranin I), a putative precursor of two novel pituitary peptides through processing at paired basic residues

  1987cited by this paper
• Chromogranins A, B, and C: Widespread Constituents of Secretory Vesicles a

  1987cited by this paper
• CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects.

  1987cited by this paper
• Diagnosis of Alzheimer's disease.

  1985influential reference
• Immunocytochemical localization of a novel pituitary protein (7B2) within the rat brain and hypophysis.

  1985cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• The Global Deterioration Scale for assessment of primary degenerative dementia.

  1982cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Molecular requirements of chromogranin B for the long-sought anion shunter of regulated secretion.

  2025cites this paper
• Chromogranin B: A versatile neuroendocrine protein regulating physiological and metabolic functions.

  2025cites this paper
• Peptidomic analysis of CSF reveals new biomarker candidates for amyotrophic lateral sclerosis

  2025cites this paper
• Protective exercise responses in the dentate gyrus of Alzheimer’s disease mouse model revealed with single-nucleus RNA-sequencing

  2025cites this paper
• Identification of novel biomarkers linking depressive disorder and Alzheimer’s disease based on an integrative bioinformatics analysis

  2023cites this paper
• Bioinformatic analysis of the SPs and NFTs proteomes unravel putative biomarker candidates for Alzheimer's disease

  2023cites this paper
• Changes of protein phosphorylation are associated with synaptic functions during the early stage of Alzheimer's disease.

  2019cites this paper
• A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease

  2017cites this paper
• Astrocyte Transcriptome from the Mecp2308-Truncated Mouse Model of Rett Syndrome

  2015cites this paper
• Chromogranin B: intra‐ and extra‐cellular mechanisms to regulate catecholamine storage and release, in catecholaminergic cells and organisms

  2014cites this paper
• Monitoring CSF Proteome Alterations in Amyotrophic Lateral Sclerosis: Obstacles and Perspectives in Translating a Novel Marker Panel to the Clinic

  2012cites this paper
• Enrichment of the inositol 1,4,5-trisphosphate receptor/Ca2+ channels in secretory granules and essential roles of chromogranins.

  2012cites this paper
• ALS genetic modifiers that increase survival of SOD1 mice and are suitable for therapeutic development.

  2011cites this paper
• PE-11, a peptide derived from chromogranin B, in the rat eye.

  2011cites this paper
• Chromogranin B Gene Ablation Reduces the Catecholamine Cargo and Decelerates Exocytosis in Chromaffin Secretory Vesicles

  2010cites this paper
• Neuronal over‐expression of chromogranin A accelerates disease onset in a mouse model of ALS

  2010cites this paper
• An overview of chromogranins

  2010cites this paper
• Chromogranins A and B as Regulators of Vesicle Cargo and Exocytosis

  2010cites this paper
• Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain

  2010cites this paper
• Chromogranins as regulators of exocytosis

  2010cites this paper
• Secretoneurin is a Neuropeptide Regulating Luteinizing Hormone Release from Pituitary Gonadotrophs

  2010cites this paper
• Synaptic degeneration in Alzheimer’s disease

  2009cites this paper
• IP3 Receptor and Ca2+ Signaling

  2009cites this paper
• New insights into granin-derived peptides: evolution and endocrine roles.

  2009cites this paper
• Striatal Alterations of Secretogranin-1, Somatostatin, Prodynorphin, and Cholecystokinin Peptides in an Experimental Mouse Model of Parkinson Disease*S

  2009cites this paper
• Anterior thalamic lesions produce chronic and profuse transcriptional de-regulation in retrosplenial cortex: A model of retrosplenial hypoactivity and covert pathology.

  2008cites this paper
• Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration.

  2008cites this paper
• Chromogranin B and Secretogranin II in Transgenic Mice Overexpressing Human APP751 with the London (V717I) and Swedish (K670M/N671L) Mutations and in Alzheimer Patients

  2008cites this paper
• O4‐01–08: Neurodegeneration and neuroinflammation in cdk5/p25 inducible mice: A model for hippocampal sclerosis and neocortical degeneration

  2008cites this paper
• Cromogranina A. La familia cromogranina-secretogranina

  2008cites this paper
• Molecular Profiling and Imaging of Peptides, Proteins and Drugs in Biological Tissue using Mass Spectrometry

  2008cites this paper
• Chromogranin B and Secretogranin II in Transgenic Mice Overexpressing Human APP751 with the London (V717I) and Swedish (K670M/N671L) Mutations and in

  2008cites this paper
• Chromogranins A and B and secretogranin II: evolutionary and functional aspects

  2007cites this paper
• The dentate gyrus in Alzheimer's disease.

  2007cites this paper
• Inositol 1,4,5 trisphosphate receptor and chromogranin B are concentrated in different regions of the hippocampus

  2007influential citation
• Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis

  2006cites this paper
• The Inositol 1,4,5-Trisphosphate Receptor (IP3R) and Its Regulators: Sometimes Good and Sometimes Bad Teamwork

  2006cites this paper
• Amyloid-beta-stimulated plasminogen activation by tissue-type plasminogen activator results in processing of neuroendocrine factors.

  2005cites this paper
• Proteomic approaches in drug discovery and development.

  2004cites this paper
• Functional Coupling of Chromogranin with the Inositol 1,4,5-Trisphosphate Receptor Shapes Calcium Signaling*

  2004cites this paper
• Chromogranin peptides in Alzheimer's disease.

  2004cites this paper
• No evidence for loss of hippocampal neurons in non‐Alzheimer dementia patients

  2004cites this paper
• Synaptic proteins in Alzheimer’s disease

  2002cites this paper
• Reduction of chromogranin B-like immunoreactivity in distinct subregions of the hippocampus from individuals with schizophrenia.

  2002cites this paper